Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
The phosphodiesterase 4 inhibitor SB 207499 selectively inhibits neutrophil functions Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001
Phosphodiesterase expression and activity in human airways Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004
The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
The PDE4 inhibitor roflumilast N-oxide partly reversed TGFß1-induced changes in collagen I and E-cadherin expression in human airway epithelial cells Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
COX inhibition enhances remodelling processes in human lung fibroblasts Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010
The combination of PDE4 and PDE5 inhibitors reduces YAP expression in IPF Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017
Effects of PDE4 inhibitors on eotaxin-3 (CCL26) expression in lung epithelial cells Source: Annual Congress 2009 - Epithelial cell biology Year: 2009
In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236 Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019
A selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in guinea-pig antigen challenge and ferret emesis models Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
The mechanism of plasminogen activator inhibitor type-1 (PAI-1) Cys mutants inhibitory activity towards lung capillaries endothelial cells (HMVEC-L) Source: Eur Respir J 2005; 26: Suppl. 49, 93s Year: 2005
Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004 Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
Proapoptotic and anti-proliferative effect of the stable plasminogen activator inhibitor type 1 (PAI-1) mutant on the lung cancer and endothelial cells Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009
Effects of a selective phosphodiesterase IV and V inhibitor in a murine model of chronic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
The effect of an oral phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in primate asthma models Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
PP110 – Modulation of the TGF-ß-induced epithelial-to-mesenchymal transition by panselective PDE inhibitors in A549 cells Source: ERS Lung Science Conference 2021 Year: 2021
Effect of phosphodiesterase 4 (PDE-4) inhibitor – rolipram with or without co-administration of dexamethasone on experimental asthma - guinea pig model Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Roflumilast N-oxide (RNO) increases MAP kinase phosphatase-1 (MKP-1) expression in human lung fibroblasts (HLF) Source: Annual Congress 2010 - Lung cell biology and immunology Year: 2010
Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts Source: Eur Respir J 2008; 32: 555-562 Year: 2008